Trevi Therapeutics (TRVI) Cash from Operations (2018 - 2026)

Trevi Therapeutics' Cash from Operations history runs 9 years deep, the most recent figure standing at 16689000.0 for Q1 2026.

• In Q1 2026, Cash from Operations fell 23.83% year-over-year to 16689000.0; the TTM figure through Mar 2026 stood at 45301000.0 (down 9.78% YoY), while the FY2025 annual figure was 42089000.0, down 10.02% from the prior year.
• Cash from Operations was 16689000.0 for Q1 2026 at Trevi Therapeutics, down from 7631000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 6176000.0 in Q2 2022 to a low of 16689000.0 in Q1 2026.
• Historically, Cash from Operations has averaged 9230529.41 across 5 years, with a median of 8683000.0 in 2024.
• The sharpest annual moves came in 2022 and 2023: Cash from Operations gained 21.8% in 2022, then tumbled 59.89% in 2023.
• A 5-year view of Cash from Operations shows it stood at 6331000.0 in 2022, then dropped by 0.44% to 6359000.0 in 2023, then plunged by 50.18% to 9550000.0 in 2024, then rose by 20.09% to 7631000.0 in 2025, then tumbled by 118.7% to 16689000.0 in 2026.
• The last three Cash from Operations figures came in at 16689000.0 (Q1 2026), 7631000.0 (Q4 2025), and 10880000.0 (Q3 2025), per Business Quant data.